Skip to main content
Premium Trial:

Request an Annual Quote

DNAnexus Closes $68M Financing Round

NEW YORK (GenomeWeb) – DNAnexus said today that it has closed a $68 million Series F round of venture funding. Existing investors GV — formerly Google Ventures — Foresite Capital, TPG Biotech, WuXi NextCode, and Claremont Creek Ventures participated, while Innovatus Capital Partners provided both debt and equity financing.

Mountain View, California-based DNAnexus said that the new capital will support deployment of DNAnexus Apollo, a recently released platform for multi-omics and clinical data science exploration, analysis, and discovery.

"The financing enables further development of our translational research solutions, as well as continued growth in genomics with cloud-based solutions for research, clinical diagnostics, and clinical trials," CEO Richard Daly said in a statement. "The next wave of biomedical insights will be derived from cross-institutional collaborations that generate massive volumes of clinical and multi-omics data," he predicted.

DNAnexus last announced new investment in January 2018, when it closed a $58 million Series E round of venture capital. With the additional $68 million, the company has now raised about $208 million since 2009.


The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.